CAMBRIDGE, Mass.--(BUSINESS WIRE)--April 3, 2006--Biogen Idec (NASDAQ: BIIB - News) announced today that data published in the March 14, 2006 issue of Neurology demonstrated that AVONEX delayed the risk of developing clinically definite multiple sclerosis (MS) for up to five years in patients who began treatment immediately after their initial MS attack.
